Drug “hit list” won't severely affect family doctors

Article Overview

This article explains a Medicare drug-pricing policy change issued by HCFA and discusses how it may affect reimbursement for certain outpatient drugs. It focuses on the reaction of family physicians and other medical groups, the uncertainty around carrier adoption and price-list updates, and the broader legislative and lobbying context behind the pricing dispute. The piece is relevant to physicians, practice managers, and coding or reimbursement professionals tracking drug payment policy.